No significant change was observed in ACQ-7, blood eosinophils or forced expiratory volume in 1 s between days 0 and 8.
Primary care prescription pick-up data was available for 35 participants. 26 (74.3%) had a >80% pick-up rate. There was no relationship between prescription pick-up rate and F ENO suppression ( p=0.24). Table 1 presents the change in outcomes after DOICS depending on F ENO suppression status. Patients were followed-up for median 10 months (range 6-14 months). 22 patients were recommended for treatment with biologics (mepolizumab; n=16; omalizumab, n=6) with 17 patients taking biologics at the time of follow-up (mepolizumab, n=11; omalizumab, n=6). The median time to biologic initiation following DOICS was 2 months (range 0-8 months). For those receiving biologics, the median treatment duration during follow-up was 10 months (range 5-17 months).
Exacerbation rate significantly reduced following DOICS compared to the year before (average decrease of 3.76 exacerbations per year, p<0.01). There was no difference in exacerbation rate reduction in those that went onto biologics compared with those that did not ( p=0.14).
This is the first prospective study of F ENO suppression testing during routine assessment for biologic therapy in asthma. Overall, F ENO significantly reduced during DOICS. Individuals with significant F ENO suppression were younger on average and were significantly less likely to be recommended biologics. Despite this, they experienced a similar reduction in exacerbations to those that did not suppress and were more likely to be recommended for biologics. Although this real-world study is not designed or powered to detect small differences in exacerbation rate, our findings suggest that the majority of patients that achieve F ENO suppression during DOICS can improve their asthma control without the need for biologic therapy.
A number of patients recommended for biologic treatment did not receive a biologic during follow-up. This was either due to patient choice or failure to attend their appointment for biologic initiation. As a result, although the proportion of patients receiving a biologic was higher in the non-F ENO suppressor group, this did not reach statistical significance.
All participants received inhaler technique training and adherence advice during routine care. However, despite participants self-reporting good adherence, nearly half had significant F ENO suppression. Sustained improvement in adherence is likely responsible for the reduction in exacerbations in those not commencing biologics. This may be due to positive behavioural feedback provided by F ENO suppression. A proportion of patients opted to remain on once-daily Relvar Ellipta following DOICS, which may also have impacted adherence. There was no significant relationship between prescription pick-up rate assessed by reviewing primary care records and F ENO suppression response. This suggests that in our cohort, having a high prescription pick-up rate does not indicate adherence as defined by F ENO suppression testing. Although F ENO suppression identified a cohort of patients that experienced clinical improvement without biologics, one fifth of F ENO suppressors did require biologic therapy due to continued exacerbations. Adherence assessment is complex and we feel that F ENO suppression alone should not preclude treatment with biologics [11] . Newer technologies, including digital inhaler devices [12] , may enhance adherence assessment and enable F ENO suppression testing to be undertaken remotely.
MCNICHOLL et al. [10] demonstrated that a F ENO reduction of >42% on day 5 was consistent with suboptimal ICS adherence. The F ENO suppression testing protocol used in the severe asthma centres in this study undertook DOICS over 8 days with a subgroup undergoing F ENO measurement on day 4. This method appears useful for identifying a cohort of patients in whom biologic therapy is likely to be required (nonsuppressors) and those where it may not (suppressors). It is noteworthy that almost half of patients that achieved significant F ENO suppression by day 8 had suppressed by day 4. In these patients, DOICS could be stopped early, reducing the burden on the clinical team. Those that fail to suppress by day 4 should continue with DOICS for 8 days. It is unclear if longer periods of DOICS would cause F ENO suppression in additional patients.
This is a real-world, study and the relatively small sample size and observational nature limit its generalisability. However, it is currently the largest prospective patient cohort in which the relationship between F ENO suppression testing with DOICS and subsequent asthma management is examined in asthmatics otherwise meeting criteria for biologic therapy.
F ENO suppression testing using DOICS is practical and feasible during assessment for biologic therapy in severe asthmatics. There is a clear relationship between F ENO suppression and subsequent recommendation for biologic treatment. This supports a role for F ENO suppression testing in clinical practice, with potential to prevent the need for biologics in a cohort of otherwise eligible patients.
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